JNK-Induced MCP-1 Production in Spinal Cord Astrocytes Contributes to Central Sensitization and Neuropathic Pain
Open Access
- 1 April 2009
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 29 (13), 4096-4108
- https://doi.org/10.1523/jneurosci.3623-08.2009
Abstract
Our previous study showed that activation of c-jun-N-terminal kinase (JNK) in spinal astrocytes plays an important role in neuropathic pain sensitization. We further investigated how JNK regulates neuropathic pain. In cultured astrocytes, tumor necrosis factor α (TNF-α) transiently activated JNK via TNF receptor-1. Cytokine array indicated that the chemokine CCL2/MCP-1 (monocyte chemoattractant protein-1) was strongly induced by the TNF-α/JNK pathway. MCP-1 upregulation by TNF-α was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1. Spinal injection of TNF-α produced JNK-dependent pain hypersensitivity and MCP-1 upregulation in the spinal cord. Furthermore, spinal nerve ligation (SNL) induced persistent neuropathic pain and MCP-1 upregulation in the spinal cord, and both were suppressed by D-JNKI-1. Remarkably, MCP-1 was primarily induced in spinal cord astrocytes after SNL. Spinal administration of MCP-1 neutralizing antibody attenuated neuropathic pain. Conversely, spinal application of MCP-1 induced heat hyperalgesia and phosphorylation of extracellular signal-regulated kinase in superficial spinal cord dorsal horn neurons, indicative of central sensitization (hyperactivity of dorsal horn neurons). Patch-clamp recordings in lamina II neurons of isolated spinal cord slices showed that MCP-1 not only enhanced spontaneous EPSCs but also potentiated NMDA- and AMPA-induced currents. Finally, the MCP-1 receptor CCR2 was expressed in neurons and some non-neuronal cells in the spinal cord. Together, we have revealed a previously unknown mechanism of MCP-1 induction and action. MCP-1 induction in astrocytes after JNK activation contributes to central sensitization and neuropathic pain facilitation by enhancing excitatory synaptic transmission. Inhibition of the JNK/MCP-1 pathway may provide a new therapy for neuropathic pain management.Keywords
This publication has 79 references indexed in Scilit:
- Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNFαNeuroscience Letters, 2008
- Activation of JNK pathway in persistent painNeuroscience Letters, 2008
- Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic painNature Medicine, 2008
- Chemokines and the pathophysiology of neuropathic painProceedings of the National Academy of Sciences of the United States of America, 2007
- Monocyte chemoattractant protein‐1 functions as a neuromodulator in dorsal root ganglia neuronsJournal of Neurochemistry, 2007
- Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brainJournal of Comparative Neurology, 2006
- Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal KinasesMicrobiology and Molecular Biology Reviews, 2006
- Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathwayNeuron Glia Biology, 2006
- Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuliGlia, 2003
- Expression of chemokines and their receptors in human and simian astrocytes: Evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulationGlia, 2003